Page 1 of 115
NR566 Final Exam 2026–2027 Latest Update | Comprehensive
Practice Questions, Detailed Answer Explanations, Complete
Study Review & Exam Preparation Guide PDF
Exam Coverage Summary
This comprehensive NR566 examination covers all essential domains including: hormone replacement therapy
alternatives (SERMs, bisphosphonates, calcitonin); women's health pharmacology (estrogen preparations, progestin
therapy, oral contraceptives, dysfunctional uterine bleeding); men's health (androgen therapy, BPH treatments,
erectile dysfunction); sexually transmitted infections (chlamydia, gonorrhea, bacterial vaginosis, herpes,
trichomoniasis, syphilis); Parkinson's disease management (levodopa, dopamine agonists, MAO-B inhibitors,
COMT inhibitors, amantadine); migraine treatment (triptans, ergot alkaloids, preventive medications, NSAIDs);
psychiatric disorders (bipolar disorder, major depressive disorder, anxiety disorders, panic disorder); antidepressant
classes (SSRIs, SNRIs, TCAs, MAOIs); antipsychotic medications (first-generation and second-generation);
insomnia treatments (benzodiazepines, non-benzodiazepines, melatonin receptor agonists); Alzheimer's disease
medications (cholinesterase inhibitors, NMDA antagonists); herbal supplements and interactions (St. John's Wort,
ginkgo, echinacea, black cohosh); and adverse effect monitoring and drug interactions.
Multiple Choice Questions
1. A 55-year-old woman with osteoporosis is concerned about the risks of hormone replacement therapy. Which of
the following medications would be an appropriate alternative for reducing fracture risk while avoiding estrogen's
adverse effects?
A. Raloxifene or alendronate
,Page 2 of 115
B. Tamoxifen only
C. Progestin only
D. Estradiol transdermal patch
Raloxifene (a SERM) and bisphosphonates like alendronate provide bone protection without the risks associated
with estrogen therapy, including increased risk of breast cancer and thromboembolic events.
2. A 45-year-old woman presents with dysfunctional uterine bleeding. The nurse practitioner should anticipate
prescribing which course of treatment?
A. Estrogen therapy for 30 days
B. Progestin for 10-14 days
C. Tamoxifen for 21 days
D. Raloxifene indefinitely
Dysfunctional uterine bleeding is typically treated with a 10-14 day course of progestin to stabilize the endometrial
lining and control bleeding. This approach helps regulate the menstrual cycle and prevent further episodes.
3. A 30-year-old woman with amenorrhea has low estrogen levels and wishes to induce menstrual flow. The nurse
practitioner should prescribe:
A. Estradiol for 10 days
B. Progestin for 5-10 days
C. Tamoxifen for 14 days
,Page 3 of 115
D. Raloxifene for 21 days
When estrogen levels are low, progestin administered for 5-10 days helps induce menstrual flow by causing
withdrawal bleeding after progestin withdrawal. This mimics normal hormonal cycling and confirms endometrial
responsiveness.
4. A patient is being counseled about the advantages of the estrogen transdermal patch compared to oral estrogen.
Which of the following is a true advantage of the transdermal route?
A. Higher total estrogen dose
B. Lower risk of DVT, PE, and stroke
C. Greater fluctuation of estrogen blood levels
D. More nausea and vomiting
Transdermal estrogen patches deliver a lower total estrogen dose, have less fluctuation of estrogen blood levels,
cause less nausea and vomiting, and are associated with a lower risk of venous thromboembolism and stroke
compared to oral estrogen.
5. A 52-year-old woman is prescribed raloxifene for osteoporosis prevention. As a Selective Estrogen Receptor
Modulator (SERM), raloxifyene provides estrogen benefits while avoiding which of its drawbacks?
A. Improved bone density
B. Increased risk of breast cancer and thromboembolism
C. Reduced hot flashes
, Page 4 of 115
D. Improved lipid profile
SERMs like raloxifene provide estrogen-like benefits on bone and lipid metabolism while avoiding the increased
risk of breast cancer, endometrial cancer, and thromboembolic events associated with traditional estrogen therapy.
6. A 35-year-old woman is starting combination oral contraceptives. The "no gap" method of changing from one oral
contraceptive to another involves:
A. Taking a 7-day break between packs
B. Going straight from one type of OC to the other without taking a gap
C. Waiting one full cycle before starting the new OC
D. Taking a 3-day break between active pills
The "no gap" method involves going directly from one type of oral contraceptive to the other without taking a gap
between cycles, ensuring continuous contraceptive protection without interruption.
7. A patient is initiating oral contraceptive therapy. According to standard guidelines, backup contraception is needed
for 7 days if the OC is started on:
A. The first day of the menstrual cycle
B. The first Sunday after the onset of menses
C. Any day of the menstrual cycle
D. The fifth day of the menstrual cycle
NR566 Final Exam 2026–2027 Latest Update | Comprehensive
Practice Questions, Detailed Answer Explanations, Complete
Study Review & Exam Preparation Guide PDF
Exam Coverage Summary
This comprehensive NR566 examination covers all essential domains including: hormone replacement therapy
alternatives (SERMs, bisphosphonates, calcitonin); women's health pharmacology (estrogen preparations, progestin
therapy, oral contraceptives, dysfunctional uterine bleeding); men's health (androgen therapy, BPH treatments,
erectile dysfunction); sexually transmitted infections (chlamydia, gonorrhea, bacterial vaginosis, herpes,
trichomoniasis, syphilis); Parkinson's disease management (levodopa, dopamine agonists, MAO-B inhibitors,
COMT inhibitors, amantadine); migraine treatment (triptans, ergot alkaloids, preventive medications, NSAIDs);
psychiatric disorders (bipolar disorder, major depressive disorder, anxiety disorders, panic disorder); antidepressant
classes (SSRIs, SNRIs, TCAs, MAOIs); antipsychotic medications (first-generation and second-generation);
insomnia treatments (benzodiazepines, non-benzodiazepines, melatonin receptor agonists); Alzheimer's disease
medications (cholinesterase inhibitors, NMDA antagonists); herbal supplements and interactions (St. John's Wort,
ginkgo, echinacea, black cohosh); and adverse effect monitoring and drug interactions.
Multiple Choice Questions
1. A 55-year-old woman with osteoporosis is concerned about the risks of hormone replacement therapy. Which of
the following medications would be an appropriate alternative for reducing fracture risk while avoiding estrogen's
adverse effects?
A. Raloxifene or alendronate
,Page 2 of 115
B. Tamoxifen only
C. Progestin only
D. Estradiol transdermal patch
Raloxifene (a SERM) and bisphosphonates like alendronate provide bone protection without the risks associated
with estrogen therapy, including increased risk of breast cancer and thromboembolic events.
2. A 45-year-old woman presents with dysfunctional uterine bleeding. The nurse practitioner should anticipate
prescribing which course of treatment?
A. Estrogen therapy for 30 days
B. Progestin for 10-14 days
C. Tamoxifen for 21 days
D. Raloxifene indefinitely
Dysfunctional uterine bleeding is typically treated with a 10-14 day course of progestin to stabilize the endometrial
lining and control bleeding. This approach helps regulate the menstrual cycle and prevent further episodes.
3. A 30-year-old woman with amenorrhea has low estrogen levels and wishes to induce menstrual flow. The nurse
practitioner should prescribe:
A. Estradiol for 10 days
B. Progestin for 5-10 days
C. Tamoxifen for 14 days
,Page 3 of 115
D. Raloxifene for 21 days
When estrogen levels are low, progestin administered for 5-10 days helps induce menstrual flow by causing
withdrawal bleeding after progestin withdrawal. This mimics normal hormonal cycling and confirms endometrial
responsiveness.
4. A patient is being counseled about the advantages of the estrogen transdermal patch compared to oral estrogen.
Which of the following is a true advantage of the transdermal route?
A. Higher total estrogen dose
B. Lower risk of DVT, PE, and stroke
C. Greater fluctuation of estrogen blood levels
D. More nausea and vomiting
Transdermal estrogen patches deliver a lower total estrogen dose, have less fluctuation of estrogen blood levels,
cause less nausea and vomiting, and are associated with a lower risk of venous thromboembolism and stroke
compared to oral estrogen.
5. A 52-year-old woman is prescribed raloxifene for osteoporosis prevention. As a Selective Estrogen Receptor
Modulator (SERM), raloxifyene provides estrogen benefits while avoiding which of its drawbacks?
A. Improved bone density
B. Increased risk of breast cancer and thromboembolism
C. Reduced hot flashes
, Page 4 of 115
D. Improved lipid profile
SERMs like raloxifene provide estrogen-like benefits on bone and lipid metabolism while avoiding the increased
risk of breast cancer, endometrial cancer, and thromboembolic events associated with traditional estrogen therapy.
6. A 35-year-old woman is starting combination oral contraceptives. The "no gap" method of changing from one oral
contraceptive to another involves:
A. Taking a 7-day break between packs
B. Going straight from one type of OC to the other without taking a gap
C. Waiting one full cycle before starting the new OC
D. Taking a 3-day break between active pills
The "no gap" method involves going directly from one type of oral contraceptive to the other without taking a gap
between cycles, ensuring continuous contraceptive protection without interruption.
7. A patient is initiating oral contraceptive therapy. According to standard guidelines, backup contraception is needed
for 7 days if the OC is started on:
A. The first day of the menstrual cycle
B. The first Sunday after the onset of menses
C. Any day of the menstrual cycle
D. The fifth day of the menstrual cycle
